ROC curve analysis to predict 3‐ and 5‐year OS rates in NMMM Patients.

Por um escritor misterioso
Last updated 09 novembro 2024
ROC curve analysis to predict 3‐ and 5‐year OS rates in NMMM Patients.
ROC curve analysis to predict 3‐ and 5‐year OS rates in NMMM Patients.
Validation of the PreOperative Score to predict Post-Operative
ROC curve analysis to predict 3‐ and 5‐year OS rates in NMMM Patients.
Serum interleukin‐33 as a novel marker for long‐term prognosis and
ROC curve analysis to predict 3‐ and 5‐year OS rates in NMMM Patients.
Several New Additions to the Scientific Database - Osstell®
ROC curve analysis to predict 3‐ and 5‐year OS rates in NMMM Patients.
Predicting 3-month Functional Outcome After Endovascular
ROC curve analysis to predict 3‐ and 5‐year OS rates in NMMM Patients.
Raemaekers
ROC curve analysis to predict 3‐ and 5‐year OS rates in NMMM Patients.
Abstracts from ATTD 20147th International Conference on
ROC curve analysis to predict 3‐ and 5‐year OS rates in NMMM Patients.
Plasma Phospholipids and Sphingolipids Identify Stent Restenosis
ROC curve analysis to predict 3‐ and 5‐year OS rates in NMMM Patients.
Comparison of the Predictive Ability of the Pediatric Risk of
ROC curve analysis to predict 3‐ and 5‐year OS rates in NMMM Patients.
Development of a new screening method for faster kinship analyses
ROC curve analysis to predict 3‐ and 5‐year OS rates in NMMM Patients.
A multicenter prospective study of comprehensive metagenomic and
ROC curve analysis to predict 3‐ and 5‐year OS rates in NMMM Patients.
Comprehensive RNA-Sequencing Analysis in Serum and Muscle Reveals
ROC curve analysis to predict 3‐ and 5‐year OS rates in NMMM Patients.
Association of Glasgow coma scale and endotracheal intubation in
ROC curve analysis to predict 3‐ and 5‐year OS rates in NMMM Patients.
ROC curves for predicting the 1‐, 3‐, and 5‐year OS in the
ROC curve analysis to predict 3‐ and 5‐year OS rates in NMMM Patients.
Neurological diseases as mortality predictive factors for patients

© 2014-2024 immanuelipc.com. All rights reserved.